ArticleToxics2025
Chemical Prioritisation for Human Biomonitoring in Ireland: A Synergy of Global Frameworks and Local Perspectives.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human biomonitoring (HBM) is a critical scientific tool for assessing human exposure by quantifying chemicals and their metabolites in biological specimens such as blood and urine. This approach provides a comprehensive and accurate evaluation of internal exposures from diverse sources and exposure routes. In Ireland, establishing a national HBM programme requires a systematic chemical prioritisation process that aligns global frameworks with local public perceptions. This study integrates insights from international initiatives such as the European Joint Programme Human Biomonitoring for Europe (HBM4EU) and the Partnership for the Assessment of Risks from Chemicals (PARC)-along with HBM programmes from EU countries (Germany, France, Belgium, Norway, Slovenia, Czech Republic, and Sweden) and non-EU countries (US, Canada, South Korea, China, and New Zealand). In addition, a national survey was conducted to capture the perceptions of people in Ireland regarding chemicals of concern to develop a comprehensive priority list of chemicals and biomarkers. The broader chemical groups identified include heavy metals (lead, cadmium, mercury, arsenic, and chromium VI), plasticisers (phthalates), bisphenols, pesticides, flame retardants, PFASs (per- and polyfluoroalkyl substances), PAHs (polycyclic aromatic hydrocarbons), POPs (persistent organic compounds), VOCs (volatile organic compounds), and UV (ultraviolet) filters. This integrated, participatory approach provides a roadmap for a robust, adaptable chemical list that supports evidence-based policy decisions in HBM in Ireland and enhances public health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.